Edgewise Therapeutics Acquired by Servier for Up to $2.65 Billion
Pharmaceutical company Servier agreed to acquire Edgewise Therapeutics' muscular dystrophy business, including its experimental drug sevasemten, in a deal worth up to $2.65 billion. The transaction includes an upfront payment of $1.55 billion and potential milestone payments totaling up to $1.1 billion.
Tickers: $EWTX
Topics: acquisitions biotech pharmaceuticals